<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785391</url>
  </required_header>
  <id_info>
    <org_study_id>Diamond</org_study_id>
    <nct_id>NCT04785391</nct_id>
  </id_info>
  <brief_title>A Sample Collection Study to Validate the NEPHROCLEAR™ CCL14 Test</brief_title>
  <official_title>A Sample Collection Study to Validate the NEPHROCLEAR™ CCL14 Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astute Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astute Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this sample collection study is to collect urine samples to validate the&#xD;
      NEPHROCLEAR™ CCL14 Test in patients with KDIGO stage 2 or 3 AKI. This study is observational&#xD;
      and will have no impact on the medical management of the subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Persistent Severe Acute Kidney Injury as Determined by Physician Adjudication</measure>
    <time_frame>Within 5 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Patients with KDIGO stage 2 or 3 AKI</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine collection for NEPHROCLEAR CCL14 Test</intervention_name>
    <description>Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test</description>
    <arm_group_label>Patients with KDIGO stage 2 or 3 AKI</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ICU patients with KDIGO stage 2 or 3 AKI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 21 years of age or older;&#xD;
&#xD;
          2. Receiving care in an intensive care unit;&#xD;
&#xD;
          3. Expected to remain in the ICU for at least 48 hours after enrollment;&#xD;
&#xD;
          4. Use of indwelling urinary catheter as standard care at the time of enrollment;&#xD;
&#xD;
          5. Subject must have acute kidney injury (KDIGO Stage 2 or Stage 3) at the time of sample&#xD;
             collection;&#xD;
&#xD;
          6. Urine sample must be collected within 36 hours of meeting KDIGO Stage 2 criteria;&#xD;
&#xD;
          7. Written informed consent provided by patient or legally authorized representative&#xD;
             (LAR).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior kidney transplantation;&#xD;
&#xD;
          2. Comfort-measures-only status;&#xD;
&#xD;
          3. Already receiving dialysis (either acute or chronic) or in imminent need of dialysis&#xD;
             at the time of enrollment;&#xD;
&#xD;
          4. Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or&#xD;
             chronic);&#xD;
&#xD;
          5. Special populations, pregnant women, prisoners or institutionalized individuals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

